Charu Aggarwal, MD, MPH, the Leslye M. Heisler Assistant Professor for Lung Cancer Excellence at Perelman School of Medicine, University of Pennsylvania, and other researchers conducted a prospective study using next-generation sequencing as a biomarker to predict response and progression-free survival rates in patients with non–small cell lung cancer receiving pembrolizumab monotherapy. The data were presented during the 2019 ASCO Annual Meeting.
Charu Aggarwal, MD, MPH, the Leslye M. Heisler Assistant Professor for Lung Cancer Excellence at Perelman School of Medicine, University of Pennsylvania, and other researchers conducted a prospective study using next-generation sequencing (NGS) as a biomarker to predict response and progression-free survival rates in patients with nonsmall cell lung cancer (NSCLC) receiving pembrolizumab (Keytruda) monotherapy. The data were presented during the 2019 ASCO Annual Meeting.
How a circulating tumor DNA (ctDNA) NGS profile and serial and ctDNA NGS monitoring relates to patient response after pembrolizumab monotherapy in patients with NSCLC is unclear because of limited data. In the study, researchers gathered some of the missing data by collecting plasma at baseline, 9 weeks into treatment, and at 18 weeks into treatment. The NGS gene panel could detect 73 mutations in study patients.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More